Mediators of Inflammation

Mediators of Inflammation / 2015 / Article

Research Article | Open Access

Volume 2015 |Article ID 619480 | 7 pages | https://doi.org/10.1155/2015/619480

Molecular and Biochemical Characterization of Recombinant Guinea Pig Tumor Necrosis Factor-Alpha

Academic Editor: Stuart Gray
Received12 Jan 2015
Revised20 Mar 2015
Accepted30 Mar 2015
Published27 Apr 2015

Abstract

Tumor necrosis factor alpha (TNF-α) is a cytokine which plays opposing roles in the context of infectious disease pathogenesis. TNF-α is essential for the development of a protective immune response to some pathogens, for example, Mycobacterium tuberculosis, by synergizing with other cytokines. However, exorbitant or uncontrolled TNF-α activity may also drive pathology and disease symptoms in many infectious diseases. In order to elucidate the beneficial and detrimental roles of TNF-α in tuberculosis (TB) and other diseases for which the guinea pig is the small animal model of choice, recombinant guinea pig (rgp)TNF-α has been produced using prokaryotic expression systems. However, it is unknown whether posttranslational modifications which cannot be made in the prokaryotic expression systems may be important for rgpTNF-α structure and function. Therefore, we carried out a comparative study by expressing rgpTNF-α in prokaryotic and eukaryotic expression systems and analyzed the eukaryotic-expressed rgpTNF-α for the presence of posttranslational modifications by subjecting it to NanoLC-MS/MS. We conclude that the eukaryotic-expressed rgpTNF-α lacks posttranslational modifications, and we found no significant difference in terms of the biological activity between prokaryotic- and eukaryotic-expressed rgpTNF-α. Taken together, results from our study show that a prokaryotic expression system can be used for generating large amounts of rgpTNF-α without concern for the biological integrity.

1. Introduction

Tumor necrosis factor alpha (TNF-α) plays important and contradictory roles in the pathogenesis of many infectious diseases, including tuberculosis (TB) [1, 2]. TNF-α synergizes with other cytokines in contributing to a protective immune response in the host in TB by promoting the formation and maintenance of granulomatous lesions which are considered to be an essential part of the host’s attempts to control both the local accumulation and dissemination of the pathogen [3, 4]. Defective granuloma formation was observed in TNF-deficient mice infected with virulent Mycobacterium tuberculosis [5]. Humans treated with TNF-blocking drugs are at high risk of developing reactivation TB, reinforcing the critical role of TNF-α in the maintenance of host resistance [6]. On the other hand, uncontrolled TNF-α contributes to disease symptoms (e.g., fever and weight loss), tissue destruction, and organ pathology in TB and other chronic diseases [7]. Understanding these apparently contradictory functions of TNF-α will require the necessary reagents to study the molecule in both in vitro and in vivo studies in the small experimental animals of choice. Animal models such as mice, guinea pigs, rabbits, and monkeys are widely used in TB research [8]. The guinea pig model of pulmonary TB mimics human TB in many important ways, including the formation of typical, human-like granulomas, and other characteristic features which makes it a gold standard for evaluating novel vaccine candidates during preclinical trials [9]. Our laboratory has cloned and expressed several guinea pig cytokine and chemokine genes such as interleukin-8 (IL-8/CXCL-8) [10], regulated upon activation, normal T-cell expressed and secreted (RANTES/CCL5) [11], interferon-gamma (IFN-γ) [12], interleukin-4 (IL-4) [13], interleukin-10 (IL-10) [14], interleukin-1beta (IL-1beta) [15], monocyte chemoattractant protein-1 (MCP-1) [16], and interleukin-17 [17]. We have previously reported the generation of rgpTNF-α using a prokaryotic expression system [18] and have used this reagent to study the contributions of TNF-α to the response of both phagocytic cells and whole animals to infection with virulent M. tuberculosis [19].

The rgpTNF-α can be produced using either prokaryotic or eukaryotic expression systems. The advantages of prokaryotic expression systems are that a large amount of recombinant protein can be produced without the complication of maintaining large volumes of eukaryotic cell culture and purifying the protein from a complex matrix composed of other eukaryotic proteins [19]. On the other hand, eukaryotic expression systems have the advantage that the proteins produced may undergo posttranslational modifications which are required for their structural and biological integrity [20]. Posttranslational modifications were observed in cytokine and chemokine genes of humans and other species [21, 22].

All of our previous work with rgpTNF-α has been carried out with protein produced by E. coli [17, 23]. However, rgpTNF-α has not been generated using a eukaryotic expression system and the impact of posttranslational modifications on the structure and activity of this molecule remains to be determined. Therefore, in this study, we generated rgpTNF-α using an efficient eukaryotic expression system, analyzed the resulting protein for the presence of posttranslational modifications, and compared the biological activities of prokaryotic- and eukaryotic-expressed rgpTNF-α.

2. Materials and Methods

2.1. Prokaryotic Expression of Guinea Pig TNF-Alpha

The cloning of guinea pig TNF-α was accomplished by using the Concanavalin A-stimulated guinea pig splenocytes as described previously [24]. The construct containing coding sequence of guinea pig TNF-α was a generous gift from Dr. Teizo Yoshimura, National Cancer Institute, USA. The mature peptide region of guinea pig TNF-α (accession number-AF119622) was subcloned into the BamHI and HindIII site of pQE-30 vector (Qiagen, Chatsworth, CA) and transformed with M15 competent cells as described previously by our group [17]. Fresh transformants were obtained by streaking M15 bacterial culture containing subcloned guinea pig TNF-α in pQE-30 vector on Luria-Bertini (LB) agar plates containing 100 μg/mL ampicillin (Sigma, St. Louis, MO) and 100 μg/mL kanamycin (Sigma).

One of the transformants was inoculated into 5 milliliter (mL) of Difco-Luria-Bertini (LB) broth containing appropriate antibiotics and grown overnight at 37°C. 5 mL of the overnight culture was added to 100 mL of identical culture medium in a 250 mL flask the following day and was cultured on a shaker (220 rpm) at 37°C. When the OD600 of the culture reached 0.6, protein expression was induced by adding isopropyl-β-d-thiogalactoside (IPTG; Sigma) to a final concentration of 1.0 mM, followed by incubation for 5 hours at 37°C.

The cells were harvested by centrifugation and the pellet was resuspended in 5 mL lysis buffer following the manufacturer’s instructions [25]. The sample was sonicated and centrifuged to obtain the cleared lysate that contains rgpTNF-α.

The cleared lysate was purified by Immobilized Metal Affinity Chromatography (IMAC) employing the Ni-NTA matrix (Qiagen) as described previously for other soluble recombinant guinea pig proteins [15]. All the purification steps were performed at 4°C. The nickel-charged Ni-NTA agarose resin was added to the cleared lysate in a polypropylene column (Qiagen) in a ratio of 1 : 4 and placed on an orbital shaker for 1 hour. After equilibrating the column with 5 mL lysis buffer, the column was subjected to washing twice with 10 mL of wash buffer, followed by final elution of the His-tagged protein by the addition of the elution buffer (5 mL). A small fraction of the eluted samples were run on Novex 10–20% Tricine gel (Invitrogen, Carlsbad, CA) and the gel was stained with Coomassie brilliant blue. The eluted fractions containing TNF-α were pooled and concentrated using Amicon centrifugal filter devices (Millipore) and the concentrated protein content was estimated using the Bradford assay kit (Bio-Rad).

2.2. Eukaryotic Expression of Guinea Pig TNF-α

The eukaryotic expression vector pCEP-Pu [26] used in this study does not contain the His tag. In order to add the His tag, the mature peptide region of TNF-α cloned into BamHI and HindIII restriction sites of the pQE-30 vector were amplified with primer sequences (Invitrogen) designed to contain NheI/XhoI recognition sequences so that, upon amplification from the 5′ end, the product contained the NheI flanking sequence-His tag-mature peptide region of the guinea pig TNF-α-Xho I flanking sequence. The forward and reverse primers containing NheI and XhoI recognition sequences used for amplification were 5′-TAG CTA GCG CAT CAC CAT CAC CAT CAC GGA-3′ and 5′-TAC TCG AGC AAG CTT CTA GTT TGT TAA TTT-3′. The italicized parts of the primer sequences are complementary to the nucleotide sequences of the guinea pig TNF-α cDNA whereas the 5′ overhangs (bolded and underlined) are flanking restriction sites designed to facilitate cloning. The amplified products were digested with the NheI/XhoI enzymes (New England Biolabs), and gel eluted prior to ligation with the pCEP-Pu vector containing the same restriction sites. The ligated product was used to chemically transform XL1-Blue competent cells (Agilent Technologies, Santa Clara, CA) according to the manufacturer’s instructions and the presence of the inserts in the transformants was analyzed by restriction analysis with NheI and XhoI and subjected to Sanger sequencing.

2.3. Transfection of pCEP-Pu Vector Containing the TNF-α Gene

Human embryonic kidney (HEK) 293-EBNA cells (Invitrogen) grown in Dulbecco’s Modified Eagle Medium (Invitrogen) according to our previously published procedure [14] were grown to three-fourth confluency and transfected for 24 h with Lipofectamine 2000 (Invitrogen) using different concentrations of pCEP-Pu plasmid DNA containing the gpTNF-α cDNA. The transfection medium was then replaced with CD-293 medium without serum containing puromycin (0.05 μg/mL) and the cells were incubated at 37°C for 48 h before collecting the supernatant fluid. Purification of cell lysates containing the putative rgpTNF-α was performed in a similar manner to that described above for prokaryotic expressed rgpTNF-α.

2.4. Validation of Eukaryotic Expressed rgpTNF-α by Western Blot Analysis

The generation of polyclonal rabbit antiserum against prokaryotic-expressed rgpTNF-α has been described earlier [18]. In brief, the rgpTNF-α was mixed with the adjuvant TiterMax Gold (CytRx Corp, Norcross, GA) and injected subcutaneously into New Zealand white rabbits in four injections that were spaced at 3-week intervals. The animals were exsanguinated 5 weeks following the last booster and sera were collected by centrifugation of blood at 1500 rcf for 20 minutes. The serum was aliquoted and stored at −80°C until it was used in the Western blot assay.

Approximately 200 ng of eukaryotic-expressed rgpTNF-α protein was run on a 10–20% tricine gel (Invitrogen) and blotted onto a nitrocellulose membrane using the semidry Minitrans blot electrophoretic transfer cell apparatus (Bio-Rad). The identity of the eukaryotic-expressed rgpTNF-α was determined by its reaction to the polyclonal anti-rgpTNF-α antiserum by Western blot analysis using the WesternBreeze chromogenic kit (Invitrogen) following the manufacturer’s instructions with anti-rabbit (IgG) antibody as the secondary antibody (Invitrogen).

2.5. LC-MS/MS Analysis of Eukaryotic-Expressed rgpTNF-α for Posttranslational Modifications

The eukaryotic-expressed rgpTNF-α (approximately 500 nanograms) was run on a SDS-Tricine gel and the band corresponding to rgpTNF-α was excised from the gel and subjected to nano LC-MS/MS. In silico digestion analysis was performed to judge the protease best suited for obtaining peptides in the correct mass range prior to subjecting it to LC-MS/MS [27]. Protein digests were separated by capillary rp-HPLC prior to in-line analysis of their masses and fragmentation patterns. Final data generated were analyzed using Scaffold software (http://www.proteomesoftware.com/Scaffold/Scaffold_viewer.htm).

2.6. Biological Activity of Prokaryotic- and Eukaryotic-Expressed rgpTNF-α

The biological activity of prokaryotic- and eukaryotic-expressed rgpTNF-α was analyzed by measuring their cytotoxicity on L929 fibroblasts as previously described [28]. In brief, the L929 cell suspension in RPMI 1640 without phenol red and supplemented with 2 μM L-glutamine, 100 Units of penicillin/mL, 100 μg of streptomycin/mL, and 2% FBS, at a concentration of 4 × 105 cells/mL, were seeded in 100 μL aliquots onto 96-well plates and incubated at 37°C overnight in a 5% CO2 incubator. The following day, 50 μL of serially diluted rgpTNF-α samples and 50 μL of an 8-μg/mL actinomycin D solution (final concentration, 2 μg/mL) were added to each well and incubated for an additional 20 h. Tetrazolium reagent (WST-1; Dojindo, Kumamoto, Japan), and 1-methoxymethyl phenazinium methyl sulfate (Dojindo) were dissolved at 6 and 0.4 mM, respectively, in phosphate-buffered saline (PBS). These were mixed at a ratio of 1 : 1, and 20 μL was added to each well. The cells were incubated for 2 hours in a 5% CO2 incubator at 37°C to allow for the color reaction to develop and the reaction was terminated by adding 25 μL of 1 N sulphuric acid (H2SO4). The optical density at both 450 nm (OD450) and 630 nm (OD630) in each well was measured with a microplate reader for the test and reference wavelengths. The net change (net ) for each well was calculated as follows: net = [( of test well) − ( of TNF-α-treated control)]. Data obtained was analyzed with a standard curve generated using recombinant human TNF-α (R&D Systems Inc., Minneapolis, Minn.).

3. Results

3.1. Confirmation of Prokaryotic Expressed rgpTNF-α

Upon streaking on LB plate supplemented with antibiotics, bacterial transformants containing the cloned guinea pig TNF-α gene were obtained. Upon induction with IPTG, those transformants, generated of a protein that was visible as a 17 kDa band on a tricine gel. The rgpTNF-α protein was purified under native conditions using Ni-NTA columns, as the protein was obtained in the soluble form and was confirmed by its specific binding to antiserum obtained from rabbits immunized with prokaryotic expressed rgpTNF-α protein as described previously by our group [18].

3.2. Confirmation of Eukaryotic-Expressed rgpTNF-α

Transformation of pCEP-Pu with the mature peptide region of the gpTNF-α gene residing in the pQE-30 vector resulted in the generation of putative transformants. All five clones that were randomly selected for restriction digestion analysis confirmed the presence of the insert. Plasmid DNA sequencing of these clones revealed that the TNF-α sequence was cloned in-frame with the His tag and thrombin cleavage site of pQE-30 vector from the 5′ end. The culture supernatants were purified on NI-NTA columns (Qiagen) to produce a band which was approximately ~19 kDa and was identified as a putative 6His-rgpTNF-α in the eluted fractions by SDS-PAGE analysis. Importantly, transfection of HEK-293 EBNA cells with the empty pCEP-Pu vector (not containing the gpTNF-α gene generated using Klenow polymerase) did not generate any protein band when analyzed on a Coomassie Blue stained SDS-gel (Figure 1(a)). The eukaryotic expressed rgpTNF-α was confirmed by its specific and strong binding to antiserum obtained from rabbits immunized with prokaryotic expressed rgpTNF-α protein (Figure 1(b)).

3.3. Analysis of Posttranslational Modifications in Eukaryotic-Expressed rgpTNF-α

The expression of eukaryotic genes cloned in E. coli lack posttranslational modifications. To determine whether such modifications were introduced into rgpTNF-α by a eukaryotic expression system, the eukaryotic-expressed rgpTNF-α protein was subjected to LC-MS/MS. Analysis by Proteome software showed that 83% of the mature peptide region was detected and there are no posttranslational modifications in those regions (see Table  1 in Supplementary Material available online at http://dx.doi.org/10.1155/2015/619480). However, intentional modifications such as carbamidomethylation and deamidation were seen (Supplementary Table  1). The carbamidomethylation is a result of reduction and alkylation. It is an intentional carboxymethylation on Cys to prevent reformation of Cys-Cys disulfides and allow complete denaturation and digestion. The deamidation is a common artifact of protein purification. Glutamine, and sometimes asparagines, are easily deamidated as is oxidation of methionine (proteins are oxidized when exposed to oxidizing atmosphere after cell disruption and the cell is a reducing environment).

3.4. Biological Activity of Prokaryotic- and Eukaryotic-Expressed rgpTNF-α

Both the prokaryotic- and eukaryotic-expressed rgpTNF-α exhibited cytotoxicity on L929 fibroblasts, a standard and widely used assay for TNF-α biological activity [28] (Figure 2). A dose-dependent increase in cytotoxicity was observed with both of the recombinant proteins (Figure 2). Importantly, there was no significant difference in dose-dependent cytotoxicity between prokaryotic and eukaryotic-expressed rgpTNF-α. Thus, prokaryotic-expressed rgpTNF-α is as biologically active as eukaryotic-expressed rgpTNF-α at the same concentration in this standard bioassay.

4. Discussion

This is the first comparative biochemical characterization of rgpTNF-α produced in prokaryotic and eukaryotic expression systems. TNF-α contributes to both host resistance and disease pathology in TB and other chronic diseases [1]. The importance of TNF-α in the control of latent or persistent mycobacteria has been revealed by the high risk of reactivation TB observed in patients undergoing anti-TNF-therapy for autoimmune diseases [29]. Since approximately one-third of the world’s population is latently infected with TB [30] there is immense need to understand the role of this cytokine in the control of latent infection and precisely how its pharmacological suppression results in reactivation of TB. Such an understanding could drive the development of novel therapeutics which could be used to suppress the detrimental effects of TNF-α in autoimmune diseases without interfering with the essential host defense mechanisms that keep M. tuberculosis in check [31]. Such studies will benefit greatly from the availability of small animal models in which detailed mechanistic investigations of TNF-α at the molecular and cellular level can be conducted. The guinea pig is widely accepted to be the small animal model of choice for TB, however, knowledge of the basic biology of guinea pig cytokines and reagents with which to study them are only now developing [32].

In our work by us and others, the function of gpTNF-α was examined in a series of studies in which rgpTNF-α and polyclonal antisera were used to enhance or suppress, respectively, the cytokine’s functions ex vivo in guinea pig phagocytic cells or in vivo in whole animals infected with virulent M. tuberculosis [7, 17, 18, 24]. The choice of a prokaryotic expression system for those early studies was based upon the advantages of ease of manipulation of bacteria versus eukaryotic cells, and the high yield of protein [20]. While those studies yielded important new information about the contributions of TNF-α to TB resistance, there was always a concern that the prokaryotic-expressed rgpTNF-α did not contain posttranslational modifications which might be important for TNF-α function in the guinea pig. Therefore, we undertook the task of expressing rgpTNFα in a eukaryotic expression system and examining the protein for such modifications.

Posttranslational modifications have significant effects on the structure and function of many mammalian proteins [33, 34]. No published information is available on the posttranslational modification of any guinea pig protein. Posttranslational modifications are reported to exert significant effect on the activity of cytokine proteins [35, 36]. In recombinant TNF-α from humans, mice and rats, three of the five potential posttranslational modification sites are in the signal peptide region, where as the other two are in the mature peptide region. (http://www.phosphosite.org/proteinAction.do?id=8542247&showAllSites=true). Interestingly, all the five potentially phosphorylated amino acids are also conserved in the guinea pig (second, third, and fifth amino acids -S, T, S) as well as other mammalian species (Figure 3). However, since the mature peptide region was cloned without the need for the signal peptide region, the first three modifications were not observed. Peptides corresponding to the last two modifications were obtained in our analysis but posttranslational modifications were not observed in our analysis.

We observed no posttranslational modifications in our eukaryotic-expressed rgpTNF-α and no difference in the dose-dependent biological function in the standard L929 cell cytotoxicity assay (Figure 2; Supplementary Table  1). In addition, rabbit polyclonal antisera developed in response to prokaryotic-expressed rgpTNFα cross-reacted strongly with the eukaryotic-expressed protein (Figure 1). Additional work with the recombinant proteins, including another functional assay to validate these findings, was not possible because the laboratory in which these studies were performed has closed due the retirement of the principal investigator. Thus, we conclude that the prokaryotic expressed rgpTNF-α can be used in future studies without concern that the expression system has failed to introduce modifications which alter the protein’s biological function significantly. The prokaryotic expression system is preferred because of the ease of manipulation and the relatively higher yield. In studies comparing the yield of rgpTNF-α in the two expression systems, we observed at least 20-fold increase in the protein yield from E. coli compared to the HEK cells (Data not shown). Given the importance of the guinea pig as a small animal model of TB and other diseases [37, 38], we believe that our observations will facilitate future studies of the role of TNF-α using recombinant protein expressed in prokaryotic systems.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This work was supported by a subcontract from Colorado State University under NIH contract HHSN 266200400091c. The authors thank Dr. Gregory Bix for obtaining and providing Pcep-Pu vector and HEK-293 EBNA cell-line. The authors thank Dr. Larry Dangott of the Protein Chemistry Laboratory at Texas A&M University for successful protein sequencing and Ms. Cathryn Formichella for her technical expertise. The authors are also thankful to Mr. Paul David Ciarlariello, Ohio State University Medical Center, for helping them with the part of posttranslational modification analysis.

Supplementary Materials

Supplementary Table 1. Post-translational modification analysis of eukaryotic expressed rgpTNF-α by NanoLC-MS/MS.

  1. Supplementary Material

References

  1. V. F. J. Quesniaux, M. Jacobs, N. Allie et al., “TNF in host resistance to tuberculosis infection,” in TNF Pathophysiology. Molecular and Cellular Mechanisms, G. Kollias and P. P. Sfikakis, Eds., vol. 11 of Current Directions in Autoimmunity, pp. 157–179, Karger, Basel, Switzerland, 2010. View at: Google Scholar
  2. N. Allie, S. I. Grivennikov, R. Keeton et al., “Prominent role for T cell-derived tumour necrosis factor for sustained control of Mycobacterium tuberculosis infection,” Scientific Reports, vol. 3, article 1809, 2013. View at: Publisher Site | Google Scholar
  3. S. Ehlers, “Role of tumor necrosis factor (TNF) in host defense against tuberculosis: implications for immunotherapies targeting TNF,” Annals of the Rheumatic Diseases, vol. 62, no. 2, pp. 37–42, 2003. View at: Google Scholar
  4. I. M. Orme and R. J. Basaraba, “The formation of the granuloma in tuberculosis infection,” Seminars in Immunology, vol. 26, no. 6, pp. 601–609, 2014. View at: Publisher Site | Google Scholar
  5. T. Botha and B. Ryffel, “Reactivation of latent tuberculosis infection in TNF-deficient mice,” The Journal of Immunology, vol. 171, no. 6, pp. 3110–3118, 2003. View at: Publisher Site | Google Scholar
  6. J. Keane, “TNF-blocking agents and tuberculosis: new drugs illuminate an old topic,” Rheumatology, vol. 44, no. 6, pp. 714–720, 2005. View at: Publisher Site | Google Scholar
  7. S. Ben-Horin, U. Kopylov, and Y. Chowers, “Optimizing anti-TNF treatments in inflammatory bowel disease,” Autoimmunity Reviews, vol. 13, no. 1, pp. 24–30, 2014. View at: Publisher Site | Google Scholar
  8. A. S. Dharmadhikari and E. A. Nardell, “What animal models teach humans about tuberculosis,” The American Journal of Respiratory Cell and Molecular Biology, vol. 39, no. 5, pp. 503–508, 2008. View at: Publisher Site | Google Scholar
  9. H. McShane and A. Williams, “A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data,” Tuberculosis, vol. 94, no. 2, pp. 105–110, 2014. View at: Publisher Site | Google Scholar
  10. M. J. Lyons, T. Yoshimura, and D. N. McMurray, “Interleukin (IL)-8 (CXCL8) induces cytokine expression and superoxide formation by guinea pig neutrophils infected with Mycobacterium tuberculosis,” Tuberculosis, vol. 84, no. 5, pp. 283–292, 2004. View at: Publisher Site | Google Scholar
  11. T. A. Skwor, H. Cho, C. Cassidy, T. Yoshimura, and D. N. McMurray, “Recombinant guinea pig CCL5 (RANTES) differentially modulates cytokine production in alveolar and peritoneal macrophages,” Journal of Leukocyte Biology, vol. 76, no. 6, pp. 1229–1239, 2004. View at: Publisher Site | Google Scholar
  12. A. Jeevan, C. T. McFarland, T. Yoshimura et al., “Production and characterization of guinea pig recombinant gamma interferon and its effect on macrophage activation,” Infection and Immunity, vol. 74, no. 1, pp. 213–224, 2006. View at: Publisher Site | Google Scholar
  13. A. Jeevan, T. Yoshimura, L. H. Ly, V. R. Dirisala, and D. N. McMurray, “Cloning of guinea pig IL-4: reduced IL-4 mRNA after vaccination or Mycobacterium tuberculosis infection,” Tuberculosis, vol. 91, no. 1, pp. 47–56, 2011. View at: Publisher Site | Google Scholar
  14. V. R. Dirisala, A. Jeevan, G. Bix, T. Yoshimura, and D. N. McMurray, “Molecular cloning and expression of the IL-10 gene from guinea pigs,” Gene, vol. 498, no. 1, pp. 120–127, 2012. View at: Publisher Site | Google Scholar
  15. V. R. Dirisala, A. Jeevan, L. H. Ly, and D. N. McMurray, “Prokaryotic expression and in vitro functional analysis of IL-1β and MCP-1 from guinea pig,” Molecular Biotechnology, vol. 54, no. 2, pp. 312–319, 2013. View at: Publisher Site | Google Scholar
  16. V. R. Dirisala, A. Jeevan, S. K. Ramasamy, and D. N. McMurray, “Molecular cloning, expression, and in silico structural analysis of guinea pig IL-17,” Molecular Biotechnology, vol. 55, no. 3, pp. 277–287, 2013. View at: Publisher Site | Google Scholar
  17. T. M. Lasco, L. Cassone, H. Kamohara, T. Yoshimura, and D. N. McMurray, “Evaluating the role of tumor necrosis factor-alpha in experimental pulmonary tuberculosis in the guinea pig,” Tuberculosis, vol. 85, no. 4, pp. 245–258, 2005. View at: Publisher Site | Google Scholar
  18. H. Cho, T. M. Lasco, S. S. Allen, T. Yoshimura, and D. N. McMurray, “Recombinant guinea pig tumor necrosis factor alpha stimulates the expression of interleukin-12 and the inhibition of Mycobacterium tuberculosis growth in macrophages,” Infection and Immunity, vol. 73, no. 3, pp. 1367–1376, 2005. View at: Publisher Site | Google Scholar
  19. R. Chen, “Bacterial expression systems for recombinant protein production: E. coli and beyond,” Biotechnology Advances, vol. 30, no. 5, pp. 1102–1107, 2012. View at: Publisher Site | Google Scholar
  20. J. Andréll and C. G. Tate, “Overexpression of membrane proteins in mammalian cells for structural studies,” Molecular Membrane Biology, vol. 30, no. 1, pp. 52–63, 2013. View at: Publisher Site | Google Scholar
  21. P. Proost, S. Struyf, and J. van Damme, “Natural post-translational modifications of chemokines,” Biochemical Society Transactions, vol. 34, no. 6, pp. 997–1001, 2006. View at: Publisher Site | Google Scholar
  22. K. L. Fuson, M. Zheng, M. Craxton et al., “Structural mapping of post-translational modifications in human interleukin-24: role of N-linked glycosylation and disulfide bonds in secretion and activity,” The Journal of Biological Chemistry, vol. 284, no. 44, pp. 30526–30533, 2009. View at: Publisher Site | Google Scholar
  23. J. C. Kramp, D. N. Mcmurray, C. Formichella, and A. Jeevan, “The in vivo immunomodulatory effect of recombinant tumour necrosis factor-alpha in guinea pigs vaccinated with Mycobacterium bovis bacille Calmette-Guérin,” Clinical & Experimental Immunology, vol. 165, no. 1, pp. 110–120, 2011. View at: Publisher Site | Google Scholar
  24. A.-M. White, T. Yoshimura, A. W. Smith, J. Westwick, and M. L. Watson, “Airway inflammation induced by recombinant guinea pig tumor necrosis factor-α,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 273, no. 3, pp. L524–L530, 1997. View at: α&author=A.-M. White&author=T. Yoshimura&author=A. W. Smith&author=J. Westwick&author=&author=M. L. Watson&publication_year=1997" target="_blank">Google Scholar
  25. Qiagen, QIAexpressionist: A Handbook for High-Level Expression and Purification of 6xHis-Tagged Proteins, Qiagen, Chatsworth, Calif, USA, 2003.
  26. E. Kohfeldt, P. Maurer, C. Vannahme, and R. Timpl, “Properties of the extracellular calcium binding module of the proteoglycan testican,” FEBS Letters, vol. 414, no. 3, pp. 557–561, 1997. View at: Publisher Site | Google Scholar
  27. M. Gaspari and G. Cuda, “Nano LC-MS/MS: a robust setup for proteomic analysis,” Methods in Molecular Biology, vol. 790, pp. 115–126, 2011. View at: Publisher Site | Google Scholar
  28. T. Espevik and J. Nissen-Meyer, “A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes,” Journal of Immunological Methods, vol. 95, no. 1, pp. 99–105, 1986. View at: Publisher Site | Google Scholar
  29. J. Harris and J. Keane, “How tumour necrosis factor blockers interfere with tuberculosis immunity,” Clinical and Experimental Immunology, vol. 161, no. 1, pp. 1–9, 2010. View at: Publisher Site | Google Scholar
  30. Global Tuberculosis Report, World Health Organization, Geneva, Switzerland, 2014.
  31. M. A. Gardam, E. C. Keystone, R. Menzies et al., “Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management,” The Lancet Infectious Diseases, vol. 3, no. 3, pp. 148–155, 2003. View at: Publisher Site | Google Scholar
  32. D. J. Ordway, C. A. Shanley, M. L. Caraway et al., “Evaluation of standard chemotherapy in the guinea pig model of tuberculosis,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 5, pp. 1820–1833, 2010. View at: Publisher Site | Google Scholar
  33. N. Jenkins, L. Murphy, and R. Tyther, “Post-translational modifications of recombinant proteins: significance for biopharmaceuticals,” Molecular Biotechnology, vol. 39, no. 2, pp. 113–118, 2008. View at: Publisher Site | Google Scholar
  34. G. A. Khoury, R. C. Baliban, and C. A. Floudas, “Proteome-wide post-translational modification statistics: frequency analysis and curation of the swiss-prot database,” Scientific Reports, vol. 1, article 90, 2011. View at: Publisher Site | Google Scholar
  35. K. L. Fuson, M. Zheng, M. Craxton et al., “Structural mapping of post-translational modifications in human interleukin-24. Role of N-linked glycosylation and disulfide bonds in secretion and activity,” The Journal of Biological Chemistry, vol. 284, no. 44, pp. 30526–30533, 2009. View at: Publisher Site | Google Scholar
  36. U. Santhanam, J. Ghrayeb, P. B. Sehgal, and L. T. May, “Post-translational modifications of human interleukin-6,” Archives of Biochemistry and Biophysics, vol. 274, no. 1, pp. 161–170, 1989. View at: Publisher Site | Google Scholar
  37. A. O'Garra, P. S. Redford, F. W. McNab, C. I. Bloom, R. J. Wilkinson, and M. P. R. Berry, “The immune response in tuberculosis,” Annual Review of Immunology, vol. 31, pp. 475–527, 2013. View at: Publisher Site | Google Scholar
  38. S. Clark, Y. Hall, and A. Williams, “Animal models of tuberculosis: Guinea pigs,” Cold Spring Harbor Perspectives in Medicine, 2014. View at: Publisher Site | Google Scholar

Copyright © 2015 Vijaya R. Dirisala et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1214 Views | 507 Downloads | 3 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder